Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 105 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
1041 11.1 months Metastatic breast cancer 5 Chemotherapy
National Hospital Organization Shikoku Cancer Center Japan 10/2011
Treatment Details: Patients: This phase II study involved 80 women with pretreated metastatic breast cancer. The median age was 54.0 years. Treatment: Patients were treated with the chemotherapy agent er
 
1042 11.1 months GBM 5 Biologic therapy
Chemotherapy
Radiation
University Hospital France 4/2014
Treatment Details: Patients: This phase 2 study involved glioblastoma patients who were divided into two treatment groups. Group A consisted of 60 patients with a median age of 60.2 years, 56.7% of whom were
 
1043 11.1 months GBM 5 Chemotherapy
Radiation
University Hospital France 4/2014
Treatment Details: Patients: This phase 2 study involved glioblastoma patients who were divided into two treatment groups. Group A consisted of 60 patients with a median age of 60.2 years, 56.7% of whom were
 
1044 11.1 months Metastatic melanoma 4 Immunotherapy
Human Immune Therapy Center, University of Virginia United States 8/2013
Treatment Details: Patients: This phase 2 study involved metastatic melanoma patients who were divided into four separate treatment groups. Group A had 47 patients with a median age of 65 years; 56.1% were m
 
1045 11.1 months Recurrent ovarian cancer 4 Biologic therapy
Chemotherapy
Kliniken Essen-Mitte Germany 12/2013
Treatment Details: Patients: This phase 2 study involved 15 recurrent ovarian cancer patients who had received prior chemotherapy. The median patient age was 60 years. Treatment: Patients received chemot
 
1046 11.1 months Recurrent epithelial ovarian cancer 5 Chemotherapy
University Hospital Leuven Belgium 11/2013
Treatment Details: Patients: This phase 2 study involved 69 recurrent epithelial ovarian cancer patients with a median age of 61 years. Treatment: Patients received chemotherapy with etirinotecan pegol.
 
1047 11.1 months Metastatic Melanoma 5 Biologic therapy
Memorial Sloan-Kettering Cancer Center United States 8/2014
Treatment Details: Patients: This phase 2 study involved metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 52 patients with a median age 63.0 years and 71
 
1048 11.1 months Hormone refractory prostate cancer 4 Chemotherapy
Centre Jean Perrin France 2/2006
Treatment Details: Patients: This Phase II study involved 40 men with metastatic hormone-refractory prostate cancer. None of the patients had chemotherapy before the study. The patients were randomized into
 
1049 11.1 months Metastatic renal cell carcinoma 4 Chemotherapy
Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins United States 10/2008
Treatment Details: Patients: This phase 2 study involved 25 patients with metastatic kidney cancer (renal cell carcinoma). There were 13 men and 12 women, with a median age of 60 years. These patients ranged
 
1050 11.1 months Recurrent non-small-cell lung cancer 4 Chemotherapy
National Cancer Center Hospital East Japan 7/2003
Treatment Details: Patients: This Phase I/II trial involved 29 patients with recurrent non-small-cell lung cancer. The majority of patients had adenocarcinoma and were stage IV. Treatment: The treatment c
 
Page 105 of 187  | Previous Page  | Next Page